# Peroxitech Inc.

> Peroxitech is a University of Pennsylvania spinout developing PIP-2, a liposome-delivered nine-amino-acid peptide intended to interrupt an oxidative-injury cascade upstream of NOX1/2 activation. The Philadelphia company has built preclinical evidence in cells, mice and pigs, raised a $25 million Series A led by the Perceptive Xontogeny Venture Fund, and is now publicly listed by Penn among startups raising Series B capital. Its argument is intriguing but unfinished: stop the cellular machinery from producing a damaging burst of reactive oxygen species instead of trying to mop up the damage afterward.

- **Founded:** 2016
- **Headquarters:** Philadelphia, United States
- **Founders:** Aron B. Fisher, MD (Scientific Co-Founder), Sheldon I. Feinstein, PhD (Scientific Co-Founder), Thomas Han (CEO & Co-Founder)
- **Team size:** 1 employee in the supplied company dataset; the public team page identifies three founders.
- **Products:** PIP-2, Donor-lung preservation research program
- **Notable:** Identified nine-amino-acid peptide sequences that inhibited peroxiredoxin 6 phospholipase A2 activity and NOX2 activation in published research., Reported protection, rescue and survival benefits in multiple preclinical acute-lung-injury models., Secured NIH support for acute-lung-injury development in 2020 and donor-lung preservation research in 2022.

## Products & services

- **PIP-2** — A liposome-encapsulated, nine-amino-acid peptide derived from human lung surfactant protein A. It inhibits the phospholipase A2 activity of peroxiredoxin 6, aiming to prevent downstream NOX1/2 activation and damaging reactive oxygen production in acute lung injury.
- **Donor-lung preservation research program** — An NIH-supported research effort announced in 2022 to evaluate whether the company's therapeutic approach could reduce oxidative damage and extend donor-lung storage and viability.

## Achievements

- Identified nine-amino-acid peptide sequences that inhibited peroxiredoxin 6 phospholipase A2 activity and NOX2 activation in published research.
- Reported protection, rescue and survival benefits in multiple preclinical acute-lung-injury models.
- Secured NIH support for acute-lung-injury development in 2020 and donor-lung preservation research in 2022.
- Raised a $25 million Series A led by the Perceptive Xontogeny Venture Fund in December 2022.
- Published a 2024 porcine study in which PIP-2 reduced lung injury, cardiovascular instability and early euthanasia in an LPS-induced sepsis-like model.
- Was listed by Penn Center for Innovation among startups raising Series B capital in 2026.

## Latest updates

- **2026-01** — Penn Center for Innovation listed Peroxitech as a Series B company raising capital and described it as developing a novel peptide for acute lung injury.
- **2024-05** — A PLOS One paper reported that liposomal PIP-2 reduced oxidative and inflammatory responses in human pulmonary endothelial cells exposed to serum from patients with fatal COVID-19.
- **2024-02** — A peer-reviewed porcine study reported reduced lung injury, cardiovascular instability and early euthanasia after PIP-2 treatment in an LPS-induced sepsis-like model.
- **2022-12** — Peroxitech closed a $25 million Series A led by the Perceptive Xontogeny Venture Fund.
- **2022-08** — The company announced NIH support to study a therapeutic approach for extending donor-lung storage and viability.

## Links

- Website: https://peroxitech.com
- LinkedIn: http://www.linkedin.com/company/peroxitech

---

Profile page: https://yespress.io/peroxitech-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-22